Search

Your search keyword '"Bulzacka, Ewa"' showing total 21 results
Start Over Author "Bulzacka, Ewa"
21 results on '"Bulzacka, Ewa"'

1. Validation and refinement of the clinical staging model in a French cohort of outpatient with schizophrenia (FACE-SZ)

Author

Andrianarisoa, Méja, Aouizerate, Bruno, Berna, Fabrice, Blanc, Olivier, Brunel, Lore, Bulzacka, Ewa, Capdevielle, Delphine, Chéreau-Boudet, Isabelle, Chesnoy-Servanin, Gabrielle, Danion, Jean-Marie, D'Amato, Thierry, Deloge, Arnaud, Delorme, Claire, Denizot, Hélène, Dorey, Jean-Michel, Dubertret, Caroline, Dubreucq, Julien, Faget, Catherine, Fluttaz, Cécile, Fond, Guillaume, Fonteneau, Sandrine, Gabayet, Franck, Giraud-Baro, Elisabeth, Hardy-Baylé, Marie-Christine, Lacelle, Delphine, Lançon, Christophe, Laouamri, Hakim, Leboyer, Marion, Le Gloahec, Tifenn, Le Strat, Yann, Llorca, Pierre-Michel, Mallet, Jasmina, Metairie, Emeline, Misdrahi, David, Passerieux, Christine, Peri, Pauline, Pires, Sylvie, Portalier, Céline, Rey, Romain, Roman, Céline, Sebilleau, Mathilde, Schandrin, Aurélie, Schneider, Priscille, Schurhoff, Franck, Tessier, Arnaud, Tronche, Anne-Marie, Urbach, Mathieu, Vaillant, Florence, Vehier, Aurélie, Vidailhet, Pierre, Vilà, Estelle, Yazbek, Hanan, Zinetti-Bertschy, Anna, Godin, Ophelia, Schürhoff, Frank, Boyer, Laurent, Myrtille, Andre, Andrianarisoa, Meja, Chereau, Isabelle, Lancon, Christophe, Leignier, Sylvain, Roux, Paul, and Costagliola, Dominique

Published
2019
Full Text
View/download PDF

2. Self-reported pain in patients with schizophrenia. Results from the national first-step FACE-SZ cohort

Author

Fond, Guillaume, Boyer, Laurent, Andrianarisoa, Meja, Godin, Ophelia, Bulzacka, Ewa, Berna, Fabrice, Brunel, Lore, Coulon, Nathalie, Aouizerate, Bruno, Capdevielle, Delphine, Chereau, Isabelle, D'amato, Thierry, Denizot, Hélène, Dubertret, Caroline, Dubreucq, Julien, Faget, Catherine, Leignier, Sylvain, Mallet, Jasmina, Misdrahi, David, Rey, Romain, Lancon, Christophe, Passerieux, Christine, Schandrin, Aurélie, Urbach, Mathieu, Vidailhet, Pierre, Leboyer, Marion, Schurhoff, Franck, and Llorca, Pierre-Michel

Published
2018
Full Text
View/download PDF

3. Advanced Paternal Age is associated with earlier schizophrenia onset in offspring. Results from the national multicentric FACE-SZ cohort

Author

Fond, Guillaume, Godin, Ophélia, Boyer, Laurent, Llorca, Pierre-Michel, Andrianarisoa, Meja, Brunel, Lore, Aouizerate, Bruno, Berna, Fabrice, Capdevielle, Delphine, D’Amato, Thierry, Denizot, Hélène, Dubertret, Caroline, Dubreucq, Julien, Faget, Catherine, Gabayet, Franck, Mallet, Jasmina, Misdrahi, David, Passerieux, Christine, Rey, Romain, Richieri, Raphaelle, Schandrin, Aurélie, Urbach, Mathieu, vidailhet, Pierre, Leboyer, Marion, Bulzacka, Ewa, and Schürhoff, Franck

Published
2017
Full Text
View/download PDF

6. Benzodiazepine long-term administration is associated with impaired attention/working memory in schizophrenia: results from the national multicentre FACE-SZ data set

Author

Fond, Guillaume, Berna, F., Boyer, L., Godin, O., Brunel, L., Andrianarisoa, M., Aouizerate, B., Capdevielle, D., Chereau, I., Danion, J. M., Dubertret, C., Dubreucq, J., Faget, C., Gabayet, F., Le Gloahec, T., Llorca, P. M., Mallet, J., Misdrahi, D., Rey, R., Richieri, R., Passerieux, C., Portalier, C., Roux, P., Vehier, A., Yazbek, H., Schürhoff, F., Bulzacka, E., Andrianarisoa, Méja, Aouizerate, Bruno, Berna, Fabrice, Blanc, Olivier, Brunel, Lore, Bulzacka, Ewa, Capdevielle, Delphine, Chéreau-Boudet, Isabelle, Chesnoy-Servanin, Gabrielle, Danion, Jean-Marie, D’Amato, Thierry, Deloge, Arnaud, Delorme, Claire, Denizot, Hélène, Dorey, Jean-Michel, Dubertret, Caroline, Dubreucq, Julien, Faget, Catherine, Fluttaz, Cécile, Fond, Guillaume, Fonteneau, Sandrine, Gabayet, Franck, Giraud-Baro, Elisabeth, Hardy-Baylé, Marie-Christine, Lacelle, Delphine, Lançon, Christophe, Laouamri, Hakim, Leboyer, Marion, Le Gloahec, Tifenn, Le Strat, Yann, Llorca, Pierre-Michel, Mallet, Jasmina, Metairie, Emeline, Misdrahi, David, Offerlin-Meyer, Isabelle, Passerieux, Christine, Peri, Pauline, Pires, Sylvie, Portalier, Céline, Rey, Romain, Roman, Céline, Sebilleau, Mathilde, Schandrin, Aurélie, Schurhoff, Franck, Tessier, Arnaud, Tronche, Anne-Marie, Urbach, Mathieu, Vaillant, Florence, Vehier, Aurélie, Vidailhet, Pierre, Vilà, Estelle, Yazbek, Hanan, Zinetti-Bertschy, Anna, and The FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group

Published
2017
Full Text
View/download PDF

7. Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics

Author

Misdrahi, David, Tessier, Arnaud, Daubigney, Antoine, Meissner, Wassilios, Schurhoff, Franck, Boyer, Laurent, Godin, Ophélia, Bulzacka, Ewa, Aouizerate, Bruno, Andrianarisoa, Meja, Berna, Fabrice, Capdevielle, Delphine, Chereau-Boudet, Isabelle, D’amato, Thierry, Dubertret, Caroline, Dubreucq, Julien, Faget-Agius, Catherine, Lançon, Christophe, Mallet, Jasmina, Passerieux, Christine, Rey, Romain, Schandrin, Aurélie, Urbach, Mathieu, Vidailhet, Pierre, Llorca, Pierre, Fond, Guillaume, Fondation FondaMental [Créteil], Université Panthéon-Sorbonne - UFR Histoire (UP1 UFR09), Université Panthéon-Sorbonne (UP1), Université de Bordeaux (UB), Institut des Maladies Neurodégénératives [Bordeaux] (IMN), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Hôpital Charles Perrens, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centres d'addictologies - Région Centre, CHU Clermont-Ferrand, Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes (UGA), Laboratoire de neuropsychologie cognitive et prise en charge des troubles de la communication schizophrénique, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Hôpital Mignot, Neuropsychiatrie : recherche épidémiologique et clinique, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), Neuropsychologie Cognitive et Physiopathologie de la Schizophrénie, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Strasbourg (UNISTRA)-Hôpital Civil de Strasbourg, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne (UCA), Université Montpellier 1 - UFR de Médecine (UM1 Médecine), Université Montpellier 1 (UM1), Université Paris 1 Panthéon-Sorbonne - UFR Histoire (UP1 UFR09), Université Paris 1 Panthéon-Sorbonne (UP1), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Laboratoire de recherches cliniques et en santé publique sur les handicaps psychique, cognitif et moteur (HANDIReSP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Neuropsychologie Cognitive et Physiopathologie de la Schizophrénie (NCPS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Civil de Strasbourg-Université de Strasbourg (UNISTRA), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Université Paris 1 Panthéon-Sorbonne - École d'Histoire (UP1 UFR09), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Centre hospitalier Charles Perrens [Bordeaux], Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), and Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Civil de Strasbourg

Subjects
antipsychotics, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, neurology, [SCCO.NEUR]Cognitive science/Neuroscience, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, movement disorders, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, ComputingMilieux_MISCELLANEOUS, schizophrenia/schizoaffective disorders
Abstract

International audience; Background: Extrapyramidal side effects (EPS) have been identified as a complication of antipsychotic treatment. Previous meta-analyses have investigated EPS prevalence and risk factors in randomized clinical trials with highly selected patients, but studies in real-world schizophrenia are missing. Objective: To examine the prevalence and clinical correlates associated with EPS in a nonselected national multicenter sample of stabilized patients with schizophrenia. Methods: Between 2010 and 2016, patients suffering from schizophrenia (DSM-IV-TR criteria) were recruited through the FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) network and data were collected during a comprehensive 1-day-long standardized evaluation. The Simpson-Angus Scale and the Abnormal Involuntary Movement Scale were used to assess drug-induced parkinsonism (DIP) and tardive dyskinesia, respectively. Results: The overall prevalence of DIP and tardive dyskinesia was 13.2% and 8.3%, respectively, in this community-dwelling sample of 674 patients. DIP was associated with negative symptoms (Positive and Negative Syndrome Scale [PANSS] subscore) (adjusted odds ratio [aOR] = 1.102, P Conclusions: Our results indicate the high prevalence of EPS in a nonselected community-dwelling clinically stable sample of outpatients with schizophrenia. In the monitoring of antipsychotic treatment, EPS should be systematically evaluated, especially when negative symptoms and disorganization or cognitive alteration are present. Monotherapy with a second-generation antipsychotic should be preferentially initiated for patients with these side effects.

Published
2019
Full Text
View/download PDF

9. Early and very early‐onset schizophrenia compared with adult‐onset schizophrenia: French FACE‐SZ database

Author

Coulon, Nathalie, primary, Godin, Ophélia, additional, Bulzacka, Ewa, additional, Dubertret, Caroline, additional, Mallet, Jasmina, additional, Fond, Guillaume, additional, Brunel, Lore, additional, Andrianarisoa, Méja, additional, Anderson, George, additional, Chereau, Isabelle, additional, Denizot, Hélène, additional, Rey, Romain, additional, Dorey, Jean‐Michel, additional, Lançon, Christophe, additional, Faget, Catherine, additional, Roux, Paul, additional, Passerieux, Christine, additional, Dubreucq, Julien, additional, Leignier, Sylvain, additional, Capdevielle, Delphine, additional, André, Myrtille, additional, Aouizerate, Bruno, additional, Misdrahi, David, additional, Berna, Fabrice, additional, Vidailhet, Pierre, additional, Leboyer, Marion, additional, and Schürhoff, Franck, additional

Published
2020
Full Text
View/download PDF

10. Hypovitaminosis D is associated with depression and anxiety in schizophrenia: results from the national FACE-SZ cohort. Running title: hypovitaminosis D, depression and anxiety in schizophrenia

Author

Fond, Guillaume, Godin, Ophelia, Schurhoff, Franck, Berna, F., Bulzacka, Ewa, Andrianarisoa, Meja, Brunel, Lore, Aouizerate, Bruno, Capdevielle, Delphine, Chereau, Isabelle, Coulon, Nathalie, d'Amato, Thierry, Dubertret, Caroline, Dubreucq, Julien, Faget, Catherine, Lancon, Christophe, Leignier, Sylvain, Mallet, Jasmina, Misdrahi, David, Passerieux, Christine, Rey, Romain, Schandrin, Aurélie, Urbach, Mathieu, Vidailhet, Pierre, Leboyer, Marion, Boyer, L., Llorca, Pierre Michel, Aix Marseille Université (AMU), Assistance Publique - Hôpitaux de Marseille (APHM), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Fondation FondaMental [Créteil], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Molecular virology and immunology – Physiopathology and therapeutic of chronic viral hepatitis (Team 18) (Inserm U955), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Université de Bordeaux (UB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Paris Diderot - Paris 7 (UPD7), Centre Référent de Réhabilitation Psychosociale [CH Alpes Isère], Centre Hospitalier Alpes Isère, Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Laboratoire de recherches cliniques et en santé publique sur les handicaps psychique, cognitif et moteur (HANDIReSP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Université de Strasbourg (UNISTRA), ANR-11-IDEX-0004,SUPER,Sorbonne Universités à Paris pour l'Enseignement et la Recherche(2011), ANR-10-COHO-0010,Psy-COH,FondaMental-Cohortes(2010), Université de Lyon, Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), 2011 Programme Hospitalier de Recherche Clinique National and the French Ministry of Health (Direction Générale de la Santé), as well as grants from Janssen Pharmaceutical Companies and the Fondation de France (PHRC-12-024-0278, Afssaps B110684-50, Comité de Protection des Personnes 2011-A00668-33), Assistance Publique-Hôpitaux de Marseille (AP-HM), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Centre de recherche en neurosciences de Lyon (CRNL)

Subjects
Depression, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Schizophrenia, Vitamin D, Anxiety, Metabolic syndrome
Abstract

International audience; ObjectiveHypovitaminosis D has been associated with respectively major depressive disorder, schizophrenia (SZ) and cognitive disorders in the general population, and with positive and negative symptoms and metabolic syndrome in schizophrenia. The objectives were (i) to determine the prevalence of hypovitaminosis D and associated factors (with a focus on depression and cognition) in a national non-selected multicentric sample of community-dwelling SZ subjects (ii) to determine the rate of SZ patients being administered vitamin D supplementation and associated factors.MethodsA comprehensive 2 daylong clinical and neuropsychological battery was administered in 140 SZ subjects included between 2015 and 2017 in the national FondaMental Expert Center (FACE-SZ) Cohort. Hypovitaminosis D was defined by blood vitamin D level 0.05), however, a trend toward significance has been found for metabolic syndrome (p = 0.06). Vitamin D supplementation has been administered during the previous 12 months in only 8.5% of the subjects but was associated with lower depressive symptoms (aOR = 0.67 [0.46–0.98], p = 0.04) and lower rate of current anxiety disorder (aOR = 0.06 [0.01–0.66], p = 0.02) compared to patients with hypovitaminosis D.ConclusionHypovitaminosis D is frequent and associated with depressive symptoms and anxiety disorders in schizophrenia. Vitamin D supplementation is associated with lower depressive and anxiety symptoms, however patients with hypovitaminosis D remain insufficiently treated.

Published
2018
Full Text
View/download PDF

11. Validation and refinement of the clinical staging model in a French cohort of outpatient with schizophrenia (FACE-SZ)

Author

Godin, Ophelia, primary, Fond, Guillaume, additional, Bulzacka, Ewa, additional, Schürhoff, Frank, additional, Boyer, Laurent, additional, Myrtille, Andre, additional, Andrianarisoa, Meja, additional, Aouizerate, Bruno, additional, Berna, Fabrice, additional, Capdevielle, Delphine, additional, Chereau, Isabelle, additional, Dorey, Jean-Michel, additional, Dubertret, Caroline, additional, Dubreucq, Julien, additional, Faget, Catherine, additional, Lancon, Christophe, additional, Leignier, Sylvain, additional, Mallet, Jasmina, additional, Misdrahi, David, additional, Passerieux, Christine, additional, Rey, Romain, additional, Roux, Paul, additional, Vidailhet, Pierre, additional, Costagliola, Dominique, additional, Leboyer, Marion, additional, Llorca, Pierre-Michel, additional, Andrianarisoa, Méja, additional, Blanc, Olivier, additional, Brunel, Lore, additional, Chéreau-Boudet, Isabelle, additional, Chesnoy-Servanin, Gabrielle, additional, Danion, Jean-Marie, additional, D'Amato, Thierry, additional, Deloge, Arnaud, additional, Delorme, Claire, additional, Denizot, Hélène, additional, Fluttaz, Cécile, additional, Fonteneau, Sandrine, additional, Gabayet, Franck, additional, Giraud-Baro, Elisabeth, additional, Hardy-Baylé, Marie-Christine, additional, Lacelle, Delphine, additional, Lançon, Christophe, additional, Laouamri, Hakim, additional, Le Gloahec, Tifenn, additional, Le Strat, Yann, additional, Metairie, Emeline, additional, Peri, Pauline, additional, Pires, Sylvie, additional, Portalier, Céline, additional, Roman, Céline, additional, Sebilleau, Mathilde, additional, Schandrin, Aurélie, additional, Schneider, Priscille, additional, Schurhoff, Franck, additional, Tessier, Arnaud, additional, Tronche, Anne-Marie, additional, Urbach, Mathieu, additional, Vaillant, Florence, additional, Vehier, Aurélie, additional, Vilà, Estelle, additional, Yazbek, Hanan, additional, and Zinetti-Bertschy, Anna, additional

Published
2019
Full Text
View/download PDF

12. Chronic Peripheral Inflammation is Associated With Cognitive Impairment ă in Schizophrenia: Results From the Multicentric FACE-SZ Dataset

Author

Bulzacka, Ewa, Boyer, Laurent, Schürhoff, Franck, Godin, Ophélia, Berna, Fabrice, Brunel, Lore, Andrianarisoa, Meja, Aouizerate, Bruno, Capdevielle, Delphine, Chereau-Boudet, Isabelle, Chesnoy-Servanin, Gabrielle, Danion, Jean-Marie, Dubertret, Caroline, Dubreucq, Julien, Faget, Catherine, Gabayet, Franck, Le Gloahec, Tifenn, Llorca, Pierre-Michel, Mallet, Jasmina, Misdrahi, David, Rey, Romain, Richieri, Raphaëlle, Passerieux, Christine, Roux, Paul, Yazbek, Hanan, Leboyer, Marion, Fond, Guillaume, Ctr, FACE-SZ FondaMental Acad, Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Fondation FondaMental [Créteil], Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Pôle de Psychiatrie et d’Addictologie, Hôpitaux Universitaires Henri-Mondor, Université Pierre et Marie Curie - Paris 6 (UPMC), INSERM Unit 708-Neuroepidemiology, Paris, France, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Hôpital Charles Perrens, Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Service Universitaire de Psychiatrie Adulte, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital La Colombière, Centres d'addictologies - Région Centre, CHU Clermont-Ferrand, Physiopathologie clinique et expérimentale de la schizophrénie, Université Louis Pasteur - Strasbourg I-IFR37-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Laboratoire de santé publique évaluation des systèmes de soins et santé perçue, Département Universitaire de Psychiatrie - [Hôpital Sainte Marguerite - APHM] (Hôpitaux Sud), Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud )-Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU), Service de psychiatrie adulte - B, Laboratoire de recherches cliniques et en santé publique sur les handicaps psychique, cognitif et moteur (HANDIReSP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Unité Académique de Psychiatrie, Centre Hospitalier de Versailles André Mignot (CHV), Laboratoire de sciences cognitives et psycholinguistique (LSCP), Département d'Etudes Cognitives - ENS Paris (DEC), École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École des hautes études en sciences sociales (EHESS)-Centre National de la Recherche Scientifique (CNRS), Interdisciplinary Institute for Neuroscience (IINS), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS), INSERM U955, équipe 15, Service de psychiatrie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Réseau de coopération scientifique en santé mentale, Fondation FondaMental [Créteil]-Fondation FondaMental [Créteil]-Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), Centre hospitalier Charles Perrens [Bordeaux], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), École normale supérieure - Paris (ENS-PSL), and Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS-PSL)

Subjects
Adult, Male, medicine.medical_specialty, [SHS.PSY]Humanities and Social Sciences/Psychology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Semantic memory, Humans, Cognitive Dysfunction, Psychiatry, Inflammation, biology, Working memory, C-reactive protein, Cognitive flexibility, Neuropsychology, Cognition, Regular Article, Middle Aged, medicine.disease, [SHS.ECO]Humanities and Social Sciences/Economics and Finance, Comorbidity, 030227 psychiatry, 3. Good health, Psychiatry and Mental health, C-Reactive Protein, Schizophrenia, quality, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Chronic Disease, biology.protein, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Psychology, 030217 neurology & neurosurgery
Abstract

International audience; Objectives: Inflammation, measured by abnormal blood C-reactive protein ă (CRP) level, has been described in schizophrenia (SZ), being ă inconsistently related to impaired cognitive functions. The aim of the ă present study is to investigate cognitive impairment associated with ă abnormal CRP levels in a large multi-centric sample of ă community-dwelling SZ patients, using a comprehensive neuropsychological ă battery. Method: Three hundred sixty-nine community-dwelling stable SZ ă subjects (76.2% men, mean age 32.7 y) were included and tested with a ă comprehensive battery of neuropsychological tests. Abnormal CRP level ă was defined as >3 mg/L. Results: Multiple factor analysis revealed that ă abnormal CRP levels, found in 104 patients (28.2%), were associated ă with impaired General Intellectual Ability and Abstract Reasoning (aOR = ă 0.56, 95% CI 0.35-0.90, P = .014), independently of age, sex, education ă level, psychotic symptomatology, treatments, and addiction ă comorbidities. Abnormal CRP levels were also associated with the decline ă of all components of working memory (respectively effect size [ ES] = ă 0.25, P = .033; ES = 0.27, P = .04; ES = 0.33, P = .006; and ES = 0.38, ă P = .004) and a wide range of other impaired cognitive functions, ă including memory (ES = 0.26, P = .026), learning abilities (ES = 0.28, P ă = .035), semantic memory (ES = 0.26, P = .026), mental flexibility (ES = ă 0.26, P = .044), visual attention (ES = 0.23, P = .004) and speed of ă processing (ES = 0.23, P = .043). Conclusion: Our results suggest that ă abnormal CRP level is associated with cognitive impairment in SZ. ă Evaluating the effectiveness of neuroprotective anti-inflammatory ă strategies is needed in order to prevent cognitive impairment in SZ.

Published
2016
Full Text
View/download PDF

15. Remission of depression in patients with schizophrenia and comorbid major depressive disorder: results from the FACE-SZ cohort.

Author

Fond, Guillaume, Boyer, Laurent, Berna, Fabrice, Godin, Ophélia, Bulzacka, Ewa, Andrianarisoa, Méja, Brunel, Lore, Aouizerate, Bruno, Capdevielle, Delphine, Chereau, Isabelle, Coulon, Nathalie, D'Amato, Thierry, Dubertret, Caroline, Dubreucq, Julien, Faget, Catherine, Leignier, Sylvain, Lançon, Christophe, Mallet, Jasmina, Misdrahi, David, and Passerieux, Christine

Subjects
DEPRESSED persons, DISEASE remission, PEOPLE with schizophrenia, QUALITY of life, CLINICAL trials
Abstract

Background: Major depressive disorder (MDD) is underdiagnosed and undertreated in schizophrenia, and has been strongly associated with impaired quality of life.AimsTo determine the prevalence and associated factors of MDD and unremitted MDD in schizophrenia, to compare treated and non-treated MDD.Method: Participants were included in the FondaMental Expert Centers for Schizophrenia and received a thorough clinical assessment. MDD was defined by a Calgary score ≥6. Non-remitted MDD was defined by current antidepressant treatment (unchanged for >8 weeks) and current Calgary score ≥6.Results: 613 patients were included and 175 (28.5%) were identified with current MDD. MDD has been significantly associated with respectively paranoid delusion (odds ratio 1.8; P = 0.01), avolition (odds ratio 1.8; P = 0.02), blunted affect (odds ratio 1.7; P = 0.04) and benzodiazepine consumption (odds ratio 1.8; P = 0.02). Antidepressants were associated with lower depressive symptoms score (5.4 v. 9.5; P < 0.0001); however, 44.1% of treated patients remained in non-remittance MDD. Nonremitters were found to have more paranoid delusion (odds ratio 2.3; P = 0.009) and more current alcohol misuse disorder (odds ratio 4.8; P = 0.04). No antidepressant class or specific antipsychotic were associated with higher or lower response to antidepressant treatment. MDD was associated with Metabolic syndrome (31.4 v. 20.2%; P = 0.006) but not with increased C-reactive protein.Conclusions: Antidepressant administration is associated with lower depressive symptom level in patients with schizophrenia and MDD. Paranoid delusions and alcohol misuse disorder should be specifically explored and treated in cases of non-remission under treatment. MetS may play a role in MDD onset and/or maintenance in patients with schizophrenia.Declaration of interestNone. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

16. Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations

Author

van Os, Jim, Rutten, Bart P., Myin-Germeys, Inez, Delespaul, Philippe, Viechtbauer, Wolfgang, van Zelst, Catherine, Bruggeman, Richard, Reininghaus, Ulrich, Morgan, Craig, Murray, Robin M., Di Forti, Marta, McGuire, Philip, Valmaggia, Lucia R., Kempton, Matthew J., Gayer-Anderson, Charlotte, Hubbard, Kathryn, Beards, Stephanie, Stilo, Simona A., Onyejiaka, Adanna, Bourque, Francois, Modinos, Gemma, Tognin, Stefania, Calem, Maria, O'Donovan, Michael C., Owen, Michael J., Holmans, Peter, Williams, Nigel, Craddock, Nicholas, Richards, Alexander, Humphreys, Isla, Meyer-Lindenberg, Andreas, Leweke, F. Markus, Tost, Heike, Akdeniz, Ceren, Rohleder, Cathrin, Bumb, J. Malte, Schwarz, Emanuel, Alptekin, Koksal, Ucok, Alp, Saka, Meram Can, Atbasoglu, E. Cem, Guloksuz, Sinan, Gumus-Akay, Guvem, Cihan, Burin, Karadag, Hasan, Soygur, Haldan, Cankurtaran, Eylem Sahin, Ulusoy, Semra, Akdede, Berna, Binbay, Tolga, Ayer, Ahmet, Noyan, Handan, Karadayi, Gulsah, Akturan, Elin, Ulas, Halis, Arango, Celso, Parellada, Mara, Bernardo, Miguel, Sanjuan, Julio, Bobes, Julio, Arrojo, Manuel, Luis Santos, Jose, Cuadrado, Pedro, Rodriguez Solano, Jose Juan, Carracedo, Angel, Garcia Bernardo, Enrique, Roldan, Laura, Lopez, Gonzalo, Cabrera, Bibiana, Cruz, Sabrina, Diaz Mesa, Eva Ma, Pouso, Maria, Jimenez, Estela, Sanchez, Teresa, Rapado, Marta, Gonzalez, Emiliano, Martinez, Covadonga, Sanchez, Emilio, Soledad Olmeda, Ma, de Haan, Lieuwe, Velthorst, Eva, van der Gaag, Mark, Selten, Jean-Paul, van Dam, Daniella, van der Ven, Elsje, van der Meer, Floor, Messchaert, Elles, Kraan, Tamar, Burger, Nadine, Leboyer, Marion, Szoke, Andrei, Schurhoff, Franck, Llorca, Pierre-Michel, Jamain, Stephane, Tortelli, Andrea, Frijda, Flora, Vilain, Jeanne, Galliot, Anne-Marie, Baudin, Gregoire, Ferchiou, Aziz, Richard, Jean-Romain, Bulzacka, Ewa, Charpeaud, Thomas, Tronche, Anne-Marie, De Hert, Marc, van Winkel, Ruud, Decoster, Jeroen, Derom, Catherine, Thiery, Evert, Stefanis, Nikos C., Sachs, Gabriele, Aschauer, Harald, Lasser, Iris, Winklbaur, Bernadette, Schlogelhofer, Monika, Riecher-Rossler, Anita, Borgwardt, Stefan, Walter, Anna, Harrisberger, Fabienne, Smieskova, Renata, Rapp, Charlotte, Ittig, Sarah, Soguel-Dit-Piquard, Fabienne, Studerus, Erich, Klosterkotter, Joachim, Ruhrmann, Stephan, Paruch, Julia, Julkowski, Dominika, Hilboll, Desiree, Sham, Pak C., Cherny, Stacey S., Chen, Eric Y. H., Campbell, Desmond D., Li, Miaoxin, Maria Romeo-Casabona, Carlos, Emaldi Cirion, Aitziber, Urruela Mora, Asier, Jones, Peter, Kirkbride, James, Cannon, Mary, Rujescu, Dan, Tarricone, Ilaria, Berardi, Domenico, Bonora, Elena, Seri, Marco, Marcacci, Thomas, Chiri, Luigi, Chierzi, Federico, Storbini, Viviana, Braca, Mauro, Minenna, Maria Gabriella, Donegani, Ivonne, Fioritti, Angelo, La Barbera, Daniele, La Cascia, Caterina Erika, Mule, Alice, Sideli, Lucia, Sartorio, Rachele, Ferraro, Laura, Tripoli, Giada, Seminerio, Fabio, Marinaro, Anna Maria, McGorry, Patrick, Nelson, Barnaby, Amminger, G. Paul, Pantelis, Christos, Menezes, Paulo R., Del-Ben, Cristina M., Tenan, Silvia H. Gallo, Shuhama, Rosana, Ruggeri, Mirella, Tosato, Sarah, Lasalvia, Antonio, Bonetto, Chiara, Ira, Elisa, Nordentoft, Merete, Krebs, Marie-Odile, Barrantes-Vidal, Neus, Cristobal, Paula, Kwapil, Thomas R., Brietzke, Elisa, Bressan, Rodrigo A., Gadelha, Ary, Maric, Nadja P., Andric, Sanja, Mihaljevic, Marina, Mirjanic, Tijana, van Os, Jim, Rutten, Bart P., Myin-Germeys, Inez, Delespaul, Philippe, Viechtbauer, Wolfgang, van Zelst, Catherine, Bruggeman, Richard, Reininghaus, Ulrich, Morgan, Craig, Murray, Robin M., Di Forti, Marta, McGuire, Philip, Valmaggia, Lucia R., Kempton, Matthew J., Gayer-Anderson, Charlotte, Hubbard, Kathryn, Beards, Stephanie, Stilo, Simona A., Onyejiaka, Adanna, Bourque, Francois, Modinos, Gemma, Tognin, Stefania, Calem, Maria, O'Donovan, Michael C., Owen, Michael J., Holmans, Peter, Williams, Nigel, Craddock, Nicholas, Richards, Alexander, Humphreys, Isla, Meyer-Lindenberg, Andreas, Leweke, F. Markus, Tost, Heike, Akdeniz, Ceren, Rohleder, Cathrin, Bumb, J. Malte, Schwarz, Emanuel, Alptekin, Koksal, Ucok, Alp, Saka, Meram Can, Atbasoglu, E. Cem, Guloksuz, Sinan, Gumus-Akay, Guvem, Cihan, Burin, Karadag, Hasan, Soygur, Haldan, Cankurtaran, Eylem Sahin, Ulusoy, Semra, Akdede, Berna, Binbay, Tolga, Ayer, Ahmet, Noyan, Handan, Karadayi, Gulsah, Akturan, Elin, Ulas, Halis, Arango, Celso, Parellada, Mara, Bernardo, Miguel, Sanjuan, Julio, Bobes, Julio, Arrojo, Manuel, Luis Santos, Jose, Cuadrado, Pedro, Rodriguez Solano, Jose Juan, Carracedo, Angel, Garcia Bernardo, Enrique, Roldan, Laura, Lopez, Gonzalo, Cabrera, Bibiana, Cruz, Sabrina, Diaz Mesa, Eva Ma, Pouso, Maria, Jimenez, Estela, Sanchez, Teresa, Rapado, Marta, Gonzalez, Emiliano, Martinez, Covadonga, Sanchez, Emilio, Soledad Olmeda, Ma, de Haan, Lieuwe, Velthorst, Eva, van der Gaag, Mark, Selten, Jean-Paul, van Dam, Daniella, van der Ven, Elsje, van der Meer, Floor, Messchaert, Elles, Kraan, Tamar, Burger, Nadine, Leboyer, Marion, Szoke, Andrei, Schurhoff, Franck, Llorca, Pierre-Michel, Jamain, Stephane, Tortelli, Andrea, Frijda, Flora, Vilain, Jeanne, Galliot, Anne-Marie, Baudin, Gregoire, Ferchiou, Aziz, Richard, Jean-Romain, Bulzacka, Ewa, Charpeaud, Thomas, Tronche, Anne-Marie, De Hert, Marc, van Winkel, Ruud, Decoster, Jeroen, Derom, Catherine, Thiery, Evert, Stefanis, Nikos C., Sachs, Gabriele, Aschauer, Harald, Lasser, Iris, Winklbaur, Bernadette, Schlogelhofer, Monika, Riecher-Rossler, Anita, Borgwardt, Stefan, Walter, Anna, Harrisberger, Fabienne, Smieskova, Renata, Rapp, Charlotte, Ittig, Sarah, Soguel-Dit-Piquard, Fabienne, Studerus, Erich, Klosterkotter, Joachim, Ruhrmann, Stephan, Paruch, Julia, Julkowski, Dominika, Hilboll, Desiree, Sham, Pak C., Cherny, Stacey S., Chen, Eric Y. H., Campbell, Desmond D., Li, Miaoxin, Maria Romeo-Casabona, Carlos, Emaldi Cirion, Aitziber, Urruela Mora, Asier, Jones, Peter, Kirkbride, James, Cannon, Mary, Rujescu, Dan, Tarricone, Ilaria, Berardi, Domenico, Bonora, Elena, Seri, Marco, Marcacci, Thomas, Chiri, Luigi, Chierzi, Federico, Storbini, Viviana, Braca, Mauro, Minenna, Maria Gabriella, Donegani, Ivonne, Fioritti, Angelo, La Barbera, Daniele, La Cascia, Caterina Erika, Mule, Alice, Sideli, Lucia, Sartorio, Rachele, Ferraro, Laura, Tripoli, Giada, Seminerio, Fabio, Marinaro, Anna Maria, McGorry, Patrick, Nelson, Barnaby, Amminger, G. Paul, Pantelis, Christos, Menezes, Paulo R., Del-Ben, Cristina M., Tenan, Silvia H. Gallo, Shuhama, Rosana, Ruggeri, Mirella, Tosato, Sarah, Lasalvia, Antonio, Bonetto, Chiara, Ira, Elisa, Nordentoft, Merete, Krebs, Marie-Odile, Barrantes-Vidal, Neus, Cristobal, Paula, Kwapil, Thomas R., Brietzke, Elisa, Bressan, Rodrigo A., Gadelha, Ary, Maric, Nadja P., Andric, Sanja, Mihaljevic, Marina, and Mirjanic, Tijana

Abstract

Recent years have seen considerable progress in epidemiological and molecular genetic research into environmental and genetic factors in schizophrenia, but methodological uncertainties remain with regard to validating environmental exposures, and the population risk conferred by individual molecular genetic variants is small. There are now also a limited number of studies that have investigated molecular genetic candidate gene-environment interactions (G x E), however, so far, thorough replication of findings is rare and G x E research still faces several conceptual and methodological challenges. In this article, we aim to review these recent developments and illustrate how integrated, large-scale investigations may overcome contemporary challenges in G x E research, drawing on the example of a large, international, multi-center study into the identification and translational application of G x E in schizophrenia. While such investigations are now well underway, new challenges emerge for G x E research from late-breaking evidence that genetic variation and environmental exposures are, to a significant degree, shared across a range of psychiatric disorders, with potential overlap in phenotype.

Published
2014

19. Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics: Results From the National FACE-SZ Cohort.

Author

Misdrahi D, Tessier A, Daubigney A, Meissner WG, Schurhoff F, Boyer L, Godin O, Bulzacka E, Aouizerate B, Andrianarisoa M, Berna F, Capdevielle D, Chereau-Boudet I, D'Amato T, Dubertret C, Dubreucq J, Faget-Agius C, Lançon C, Mallet J, Passerieux C, Rey R, Schandrin A, Urbach M, Vidailhet P, Llorca PM, and Fond G

Subjects
Adult, Antipsychotic Agents administration & dosage, Diagnostic and Statistical Manual of Mental Disorders, Female, France epidemiology, Humans, Independent Living statistics & numerical data, Male, Medication Therapy Management standards, Needs Assessment, Prevalence, Psychiatric Status Rating Scales, Risk Factors, Schizophrenia epidemiology, Antipsychotic Agents adverse effects, Dyskinesia, Drug-Induced diagnosis, Dyskinesia, Drug-Induced epidemiology, Dyskinesia, Drug-Induced prevention & control, Parkinson Disease, Secondary chemically induced, Parkinson Disease, Secondary diagnosis, Parkinson Disease, Secondary epidemiology, Parkinson Disease, Secondary prevention & control, Schizophrenia drug therapy, Tardive Dyskinesia chemically induced, Tardive Dyskinesia diagnosis, Tardive Dyskinesia epidemiology, Tardive Dyskinesia prevention & control
Abstract

Background: Extrapyramidal side effects (EPS) have been identified as a complication of antipsychotic treatment. Previous meta-analyses have investigated EPS prevalence and risk factors in randomized clinical trials with highly selected patients, but studies in real-world schizophrenia are missing., Objective: To examine the prevalence and clinical correlates associated with EPS in a nonselected national multicenter sample of stabilized patients with schizophrenia., Methods: Between 2010 and 2016, patients suffering from schizophrenia (DSM-IV-TR criteria) were recruited through the FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) network and data were collected during a comprehensive 1-day-long standardized evaluation. The Simpson-Angus Scale and the Abnormal Involuntary Movement Scale were used to assess drug-induced parkinsonism (DIP) and tardive dyskinesia, respectively., Results: The overall prevalence of DIP and tardive dyskinesia was 13.2% and 8.3%, respectively, in this community-dwelling sample of 674 patients. DIP was associated with negative symptoms (Positive and Negative Syndrome Scale [PANSS] subscore) (adjusted odds ratio [aOR] = 1.102, P < .001), first-generation antipsychotic prescription (aOR = 2.038, P = .047), and anticholinergic drug administration (aOR = 2.103, P = .017) independently of sex, age, disorganization (PANSS disorganized factor), and antipsychotic polytherapy. Tardive dyskinesia was associated with PANSS disorganized factor (aOR = 1.103, P = .049) independently of sex, age, negative symptoms, excitation, first-generation antipsychotic prescription, and benzodiazepine and anticholinergic drug administration., Conclusions: Our results indicate the high prevalence of EPS in a nonselected community-dwelling clinically stable sample of outpatients with schizophrenia. In the monitoring of antipsychotic treatment, EPS should be systematically evaluated, especially when negative symptoms and disorganization or cognitive alteration are present. Monotherapy with a second-generation antipsychotic should be preferentially initiated for patients with these side effects., (© Copyright 2019 Physicians Postgraduate Press, Inc.)

Published
2019
Full Text
View/download PDF

20. Chronic Peripheral Inflammation is Associated With Cognitive Impairment in Schizophrenia: Results From the Multicentric FACE-SZ Dataset.

Author

Bulzacka E, Boyer L, Schürhoff F, Godin O, Berna F, Brunel L, Andrianarisoa M, Aouizerate B, Capdevielle D, Chéreau-Boudet I, Chesnoy-Servanin G, Danion JM, Dubertret C, Dubreucq J, Faget C, Gabayet F, Le Gloahec T, Llorca PM, Mallet J, Misdrahi D, Rey R, Richieri R, Passerieux C, Roux P, Yazbek H, Leboyer M, and Fond G

Subjects
Adult, Chronic Disease, Cognitive Dysfunction etiology, Female, Humans, Male, Middle Aged, Schizophrenia complications, C-Reactive Protein analysis, Cognitive Dysfunction blood, Cognitive Dysfunction physiopathology, Inflammation blood, Schizophrenia blood
Abstract

Objectives: Inflammation, measured by abnormal blood C-reactive protein (CRP) level, has been described in schizophrenia (SZ), being inconsistently related to impaired cognitive functions. The aim of the present study is to investigate cognitive impairment associated with abnormal CRP levels in a large multi-centric sample of community-dwelling SZ patients, using a comprehensive neuropsychological battery., Method: Three hundred sixty-nine community-dwelling stable SZ subjects (76.2% men, mean age 32.7 y) were included and tested with a comprehensive battery of neuropsychological tests. Abnormal CRP level was defined as >3mg/L., Results: Multiple factor analysis revealed that abnormal CRP levels, found in 104 patients (28.2%), were associated with impaired General Intellectual Ability and Abstract Reasoning (aOR = 0.56, 95% CI 0.35-0.90, P = .014), independently of age, sex, education level, psychotic symptomatology, treatments, and addiction comorbidities. Abnormal CRP levels were also associated with the decline of all components of working memory (respectively effect size [ES] = 0.25, P = .033; ES = 0.27, P = .04; ES = 0.33, P = .006; and ES = 0.38, P = .004) and a wide range of other impaired cognitive functions, including memory (ES = 0.26, P = .026), learning abilities (ES = 0.28, P = .035), semantic memory (ES = 0.26, P = .026), mental flexibility (ES = 0.26, P = .044), visual attention (ES = 0.23, P = .004) and speed of processing (ES = 0.23, P = .043)., Conclusion: Our results suggest that abnormal CRP level is associated with cognitive impairment in SZ. Evaluating the effectiveness of neuroprotective anti-inflammatory strategies is needed in order to prevent cognitive impairment in SZ., (© The Author 2016. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Published
2016
Full Text
View/download PDF

21. Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations.

Author

van Os J, Rutten BP, Myin-Germeys I, Delespaul P, Viechtbauer W, van Zelst C, Bruggeman R, Reininghaus U, Morgan C, Murray RM, Di Forti M, McGuire P, Valmaggia LR, Kempton MJ, Gayer-Anderson C, Hubbard K, Beards S, Stilo SA, Onyejiaka A, Bourque F, Modinos G, Tognin S, Calem M, O'Donovan MC, Owen MJ, Holmans P, Williams N, Craddock N, Richards A, Humphreys I, Meyer-Lindenberg A, Leweke FM, Tost H, Akdeniz C, Rohleder C, Bumb JM, Schwarz E, Alptekin K, Üçok A, Saka MC, Atbaşoğlu EC, Gülöksüz S, Gumus-Akay G, Cihan B, Karadağ H, Soygür H, Cankurtaran EŞ, Ulusoy S, Akdede B, Binbay T, Ayer A, Noyan H, Karadayı G, Akturan E, Ulaş H, Arango C, Parellada M, Bernardo M, Sanjuán J, Bobes J, Arrojo M, Santos JL, Cuadrado P, Rodríguez Solano JJ, Carracedo A, García Bernardo E, Roldán L, López G, Cabrera B, Cruz S, Díaz Mesa EM, Pouso M, Jiménez E, Sánchez T, Rapado M, González E, Martínez C, Sánchez E, Olmeda MS, de Haan L, Velthorst E, van der Gaag M, Selten JP, van Dam D, van der Ven E, van der Meer F, Messchaert E, Kraan T, Burger N, Leboyer M, Szoke A, Schürhoff F, Llorca PM, Jamain S, Tortelli A, Frijda F, Vilain J, Galliot AM, Baudin G, Ferchiou A, Richard JR, Bulzacka E, Charpeaud T, Tronche AM, De Hert M, van Winkel R, Decoster J, Derom C, Thiery E, Stefanis NC, Sachs G, Aschauer H, Lasser I, Winklbaur B, Schlögelhofer M, Riecher-Rössler A, Borgwardt S, Walter A, Harrisberger F, Smieskova R, Rapp C, Ittig S, Soguel-dit-Piquard F, Studerus E, Klosterkötter J, Ruhrmann S, Paruch J, Julkowski D, Hilboll D, Sham PC, Cherny SS, Chen EY, Campbell DD, Li M, Romeo-Casabona CM, Emaldi Cirión A, Urruela Mora A, Jones P, Kirkbride J, Cannon M, Rujescu D, Tarricone I, Berardi D, Bonora E, Seri M, Marcacci T, Chiri L, Chierzi F, Storbini V, Braca M, Minenna MG, Donegani I, Fioritti A, La Barbera D, La Cascia CE, Mulè A, Sideli L, Sartorio R, Ferraro L, Tripoli G, Seminerio F, Marinaro AM, McGorry P, Nelson B, Amminger GP, Pantelis C, Menezes PR, Del-Ben CM, Gallo Tenan SH, Shuhama R, Ruggeri M, Tosato S, Lasalvia A, Bonetto C, Ira E, Nordentoft M, Krebs MO, Barrantes-Vidal N, Cristóbal P, Kwapil TR, Brietzke E, Bressan RA, Gadelha A, Maric NP, Andric S, Mihaljevic M, and Mirjanic T

Subjects
Genetic Predisposition to Disease, Humans, Schizophrenia epidemiology, Social Environment, Gene-Environment Interaction, Schizophrenia genetics, Schizophrenic Psychology
Abstract

Recent years have seen considerable progress in epidemiological and molecular genetic research into environmental and genetic factors in schizophrenia, but methodological uncertainties remain with regard to validating environmental exposures, and the population risk conferred by individual molecular genetic variants is small. There are now also a limited number of studies that have investigated molecular genetic candidate gene-environment interactions (G × E), however, so far, thorough replication of findings is rare and G × E research still faces several conceptual and methodological challenges. In this article, we aim to review these recent developments and illustrate how integrated, large-scale investigations may overcome contemporary challenges in G × E research, drawing on the example of a large, international, multi-center study into the identification and translational application of G × E in schizophrenia. While such investigations are now well underway, new challenges emerge for G × E research from late-breaking evidence that genetic variation and environmental exposures are, to a significant degree, shared across a range of psychiatric disorders, with potential overlap in phenotype., (© The Author 2014. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results